---
title: "Viridian Therapeutics, Inc. (VRDN.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/VRDN.US.md"
symbol: "VRDN.US"
name: "Viridian Therapeutics, Inc."
industry: "Biotechnology"
datetime: "2026-06-13T14:56:29.436Z"
locales:
  - [en](https://longbridge.com/en/quote/VRDN.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/VRDN.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/VRDN.US.md)
---

# Viridian Therapeutics, Inc. (VRDN.US)

## Company Overview

Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. It develops IGF-1R therapies to treat thyroid eye disease (TED), including Veligrotrug, a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered, and Elegrobart, a low-volume, infrequently dosed subcutaneous IGF-1R. The company also develops an anti-thyroid-stimulating hormone receptor (TSHR) candidate for the treatment of Graves’ disease and TED.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [www.viridiantherapeutics.com](https://www.viridiantherapeutics.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-06-13T04:30:14.000Z

**Overall: C (0.47)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 97 / 390 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 23382.78% |  |
| Net Profit YoY | -24.75% |  |
| P/B Ratio | 3.34 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 1685225385.15 |  |
| Revenue | 70918000.00 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -65.96% | E |
| Profit Margin | -508.46% | E |
| Gross Margin | -50819.86% | E |
| Revenue YoY | 23382.78% | A |
| Net Profit YoY | -24.75% | D |
| Total Assets YoY | 19.37% | A |
| Net Assets YoY | 5.22% | C |
| Cash Flow Margin | 100.04% | C |
| OCF YoY | 23382.78% | A |
| Turnover | 0.10 | E |
| Gearing Ratio | 19.39% | A |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Viridian Therapeutics, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "23382.78%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-24.75%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "3.34",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "1685225385.15",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "70918000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "-65.96%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-508.46%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "-50819.86%",
          "rating": "E"
        },
        {
          "name": "Revenue YoY",
          "value": "23382.78%",
          "rating": "A"
        },
        {
          "name": "Net Profit YoY",
          "value": "-24.75%",
          "rating": "D"
        },
        {
          "name": "Total Assets YoY",
          "value": "19.37%",
          "rating": "A"
        },
        {
          "name": "Net Assets YoY",
          "value": "5.22%",
          "rating": "C"
        },
        {
          "name": "Cash Flow Margin",
          "value": "100.04%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "23382.78%",
          "rating": "A"
        },
        {
          "name": "Turnover",
          "value": "0.10",
          "rating": "E"
        },
        {
          "name": "Gearing Ratio",
          "value": "19.39%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -5.56 | 391/390 | - | - | - |
| PB | 3.34 | 270/390 | 9.22 | 4.88 | 3.30 |
| PS (TTM) | 23.76 | 204/390 | 4937.23 | 43.29 | 27.25 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A |
| 02 | Arbutus Pharma (ABUS.US) | A | A | A | A | B | A |
| 03 | Rigel Pharma (RIGL.US) | A | A | B | A | B | A |
| 04 | CapForce Inc. (CFOR.US) | A | A | A | A | B | A |
| 05 | OpGen (OPGN.US) | B | A | A | A | B | A |

## Institutional View

### Analyst Rating Distribution

> As of 2026-06-04T04:00:00.000Z

Total Analysts: **17**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 13 | 76% |
| Overweight | 3 | 18% |
| Hold | 1 | 6% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 16.35 |
| Highest Target | 50.00 |
| Lowest Target | 20.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/VRDN.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/VRDN.US/norm.md)
- [Related News](https://longbridge.com/en/quote/VRDN.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/VRDN.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**